Literature DB >> 17588784

Hereditary thrombophilia and venous thromboembolism: critical evaluation of the clinical implications of screening.

L Mazzolai1, M A Duchosal.   

Abstract

Venous thromboembolism is a complex disease resulting from the interactions of several risk factors from diverse origins: genetic, environmental and behavioral. Numerous studies have evidenced an association between genetic thrombophilia defects and venous thromboembolism. However, the clinical relevance of genetic thrombophilia to recurrent venous thromboembolism is not clear and the risks of long-term anticoagulant treatment usually outweigh any benefits of hereditary thrombophilia screening. Therefore, in everyday clinical practice (outside of research protocols) hereditary thrombophilia screening should be performed only in cases where such testing is likely to influence patient management.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17588784     DOI: 10.1016/j.ejvs.2007.04.023

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  3 in total

1.  Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study.

Authors:  Vincent Ten Cate; Anthonie W A Lensing; Jeffrey I Weitz; Jan Beyer-Westendorf; Philip S Wells; Patrick Mismetti; Paolo Prandoni; Alexander T Cohen; Bruce L Davidson; Martin H Prins
Journal:  Haematologica       Date:  2019-03-07       Impact factor: 9.941

2.  Thrombophilia testing patterns amongst patients with acute venous thromboembolism.

Authors:  Melissa R Meyer; Daniel M Witt; Thomas Delate; Samuel G Johnson; Margaret Fang; Alan Go; Nathan P Clark
Journal:  Thromb Res       Date:  2015-10-21       Impact factor: 3.944

3.  Evaluation of the efficacy of venous thromboembolism prophylaxis guideline implementation in Japan.

Authors:  Kiyoaki Niimi; Masayoshi Kobayashi; Hiroshi Narita; Kiyohito Yamamoto; Kimihiro Komori
Journal:  Surg Today       Date:  2010-11-26       Impact factor: 2.549

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.